Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR2F2 | P24468 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | XBP1 | P17861 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SYK | P43405 | 4/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | FOS | P01100 | 4/20 | 0.43 |
| ▸ | JUN | P05412 | 4/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30736404 | 1.00 | NR2F2 (0.52) | NR2F2NPSR1KDM4EMAPTMAPK1 | |
| SCHEMBL10050288 | 0.92 | NR2F2 (0.56) | NR2F2NPSR1KDM4EMAPTMAPK1 | |
| SCHEMBL761164 | 0.90 | NR2F2 (0.60) | NR2F2NPSR1KDM4EMAPTMAPK1 | |
| SCHEMBL4070421 | 0.90 | NR2F2 (0.62) | NR2F2NPSR1KDM4EMAPTMAPK1 | |
| SCHEMBL20299361 | 0.88 | NR2F2 (0.63) | NR2F2NPSR1KDM4EMAPTMAPK1 | |
| SCHEMBL29501978 | 0.88 | NR2F2 (0.63) | NR2F2NPSR1KDM4EMAPTMAPK1 | |
| SCHEMBL23452672 | 0.87 | NR2F2 (0.53) | NR2F2NPSR1KDM4EMAPTMAPK1 | |
| SCHEMBL20329838 | 0.87 | NR2F2 (0.53) | NR2F2NPSR1KDM4EMAPTMAPK1 | |
| SCHEMBL30736374 | 0.87 | NR2F2 (0.53) | NR2F2NPSR1KDM4EMAPTMAPK1 | |
| SCHEMBL20299341 | 0.87 | NR2F2 (0.53) | NR2F2NPSR1KDM4EMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150355-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2024-05-09 | — | — | US | disclosed |
| US-20240124492-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2024-04-18 | — | — | US | disclosed |
| CN-112236431-B | Purinone Compounds and Their Use in the Treatment of Cancer | 阿斯利康(瑞典)有限公司 | 2024-02-13 | — | — | CN | disclosed |
| US-11884671-B2 | Purinone compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2024-01-30 | — | — | US | disclosed |
| US-11746118-B2 | Amino-triazolopyridine compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2023-09-05 | — | — | US | disclosed |
| US-11746118-B2 | Amino-triazolopyridine compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2023-09-05 | — | — | US | disclosed |
| US-11746118-B2 | Amino-triazolopyridine compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2023-09-05 | — | — | US | disclosed |
| EP-3807278-B1 | PURINONE DERIVATIVES AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2022-08-31 | — | — | EP | disclosed |
| CN-110177791-B | Amino-triazolopyridine compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2022-07-12 | — | — | CN | disclosed |
| US-11136340-B2 | Amino-triazolopyridine compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2021-10-05 | — | — | US | disclosed |
| US-20200048281-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2020-02-13 | — | — | US | disclosed |
| WO-2019238929-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2019-12-19 | — | — | WO | disclosed |
| EP-3558997-A1 | AMINO-TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2019-10-30 | — | — | EP | disclosed |
| US-10407446-B2 | Amino-triazolopyridine compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2019-09-10 | — | — | US | disclosed |
| US-10407446-B2 | Amino-triazolopyridine compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2019-09-10 | — | — | US | disclosed |
| US-20180194782-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20180194782-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20180194782-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| WO-2018114999-A1 | AMINO-TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018114999-A1 | AMINO-TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124492-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | DCK, TYMP, DPYD | NR2F2 3206/4885NPSR1 3142/4885KDM4E 836/4885 |
| US-20240150355-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | RECQL, PRPS1, PURB | NR2F2 3621/4885NPSR1 3102/4885KDM4E 1890/4885 |
| US-11136340-B2 | Amino-triazolopyridine compounds and their use in treating cancer | DCK, TYMP, DPYD | NR2F2 3206/4885NPSR1 3142/4885KDM4E 836/4885 |
| US-20180194782-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | DCK, TYMP, DPYD | NR2F2 3206/4885NPSR1 3142/4885KDM4E 836/4885 |
| US-11884671-B2 | Purinone compounds and their use in treating cancer | RECQL, PRPS1, PURB | NR2F2 3667/4885NPSR1 3339/4885KDM4E 2288/4885 |
| US-11746118-B2 | Amino-triazolopyridine compounds and their use in treating cancer | DCK, TYMP, DPYD | NR2F2 3206/4885NPSR1 3142/4885KDM4E 836/4885 |
| US-20200048281-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | DCK, TYMP, DPYD | NR2F2 3206/4885NPSR1 3142/4885KDM4E 836/4885 |
| US-10407446-B2 | Amino-triazolopyridine compounds and their use in treating cancer | DCK, TYMP, DPYD | NR2F2 3206/4885NPSR1 3142/4885KDM4E 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.